Full-Time

Executive Director

Global Patient Safety Operations

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$256k - $320kAnnually

Expert

San Carlos, CA, USA

This is a hybrid position, requiring some in-office days.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform

You match the following Revolution Medicines's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree required.
  • Extensive experience (15+ years) in drug safety/pharmacovigilance within the pharmaceutical or biotechnology industry, with knowledge of safety operations, GCP, GVP, clinical trial conduct, data interpretation, process management, quality management, data interpretation, and safety’s role in clinical development.
  • A history of progressive leadership responsibilities.
  • In-depth knowledge of global pharmacovigilance regulations and guidelines (e.g., FDA, EMA, ICH).
  • Strong leadership and management skills, with a track record of building and developing high-performing teams.
  • Able to think strategically, demonstrate accountability, results and solutions oriented, decisive, authentic, empowering, self-aware, and adaptable.
  • Excellent written and verbal communication, interpersonal, and influencing skills, with the ability to effectively collaborate with internal and external stakeholders.
  • Proven ability to think strategically, drive innovation, and implement process improvements in safety operations.
  • Experience interacting with regulatory agencies and participating in regulatory inspections and audits is required.
  • Expert knowledge of US, EU, and global regulations governing pharmacovigilance.
  • Expert knowledge of industry standard safety databases.
  • Strong program management skills enabling efficient planning and execution of program milestones within budget and timelines.
  • Strong vendor management skills with experience managing high profile projects with CROs and internal staff.
  • Ability to build relationships and influence across disciplines, functions, and levels.
  • Strong learning orientation and the desire to share expertise and learn from others.
  • Commitment to patients and the science that drives the shared mission at Revolution Medicines.
Responsibilities
  • In collaboration with senior leadership, develop and implement the Revolution Medicines safety operations strategy, vision, and direction, including the safety database strategy.
  • Lead the safety operations team ensuring case processing activities from all sources follow global regulations and internal requirements, create and analyze oversight metrics reports, review, approve, and trend late case investigations, ensure proper training is received and documented, and ensure the global safety database configuration is appropriate to meet Revolution Medicines needs.
  • Oversee the resourcing, budget, and management of pharmacovigilance contract research organizations (PV CROs) in safety operations activities.
  • Partner with safety science and other development staff as necessary for medical review and approval of cases inclusive of case narratives and causality assessments of AE/SAE reports.
  • In collaboration with safety science and other development staff, compile analysis of similar events (AOSE), individual case comments, REMS (Risk Evaluation and Mitigation Strategies), RMP (Risk Management Plan) analyses, and ad hoc safety analysis as required by health authorities or corporate policy.
  • Contribute to the preparation of aggregate safety reports required by health authorities.
  • Author, review and provide input and approval for drug-safety related regulatory reports and clinical study documents (including case report forms, clinical study protocols, Informed Consent Forms, Investigator Brochures, Integrated Summary of Safety (ISS), Integrated Summary of Efficacy (ISE), product package labeling, Company Core Safety Information.
  • Develop and maintain relationships across Revolution Medicines, particularly in Clinical Operations, Clinical Development, Clinical Data Science, Regulatory Affairs, Quality Assurance, Medical Affairs, and other departments as appropriate.
  • Ensure the accurate and timely completion and reporting of periodic and expedited safety reports, in compliance with internal time frames and time frames dictated by regulatory authorities.
  • Lead development of standard operating procedures for safety and internal compliance.
  • Oversee as applicable, safety vendors responsible for drafting and submitting periodic reports such as the DSUR (Development Safety Update Report) and PBRER (Periodic Benefit Risk Evaluation Report), ensuring compliance with regulations and timeliness of submission.
  • Collaborate with Safety Science to create robust processes to maintain compliance with safety requirements related to REMS/RMP.
  • In conjunction with the clinical data science and clinical operations, coordinate periodic reconciliation of the clinical and safety databases.
  • Create and maintain the Pharmacovigilance System Master File (PSMF) to support European filings and regulations as applicable.
  • Work with the EU Qualified Person Responsible for Pharmacovigilance (QPPV) to ensure European compliance as applicable.
  • Author, review, and approve pharmacovigilance agreements (PVAs), and safety data exchange agreements (SDEA) with applicable partners.
  • Responsible for ensuring inspection readiness for global inspections by ensuring all processes and training reflect global regulatory requirements.
  • Influences and communications with executive management regarding PV strategy.
Desired Qualifications
  • Advanced degrees in pharmacy, medicine, nursing, life sciences, or a related field preferred.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in net cash for R&D.
  • FDA fast-tracking RAS-targeted therapies supports their pipeline development.
  • Increased interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

7%
Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders

PharmaSources
Aug 15th, 2023
EQRx, known as the "TEMU" of the Pharmaceutical Industry, has been Acquired by Revolution Medicines

On August 1st, EQRx announced an agreement with Revolution Medicines to be acquired in an all-stock transaction, which is expected to be completed in November 2023.